Compare NVST & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | ADPT |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.5B |
| IPO Year | 2019 | 2019 |
| Metric | NVST | ADPT |
|---|---|---|
| Price | $23.28 | $24.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | $28.69 | ★ $29.81 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.31 | 63.89 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $2,566,500,000.00 | $276,976,000.00 |
| Revenue This Year | $5.80 | $5.94 |
| Revenue Next Year | $3.55 | $22.42 |
| P/E Ratio | $41.96 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $18.77 | $12.00 |
| 52 Week High | $30.42 | $30.74 |
| Indicator | NVST | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 40.00 |
| Support Level | $22.69 | $23.73 |
| Resistance Level | $23.94 | $26.51 |
| Average True Range (ATR) | 0.58 | 1.44 |
| MACD | 0.13 | -0.45 |
| Stochastic Oscillator | 57.63 | 8.42 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.